115 related articles for article (PubMed ID: 30629858)
1. Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
Osawa M; Ueno T; Shiozaki T; Ishikawa H; Li H; Garimella T
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):802-817. PubMed ID: 30629858
[TBL] [Abstract][Full Text] [Related]
2. Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.
Ueno T; Osawa M; Shiozaki T; Green M; Garimella T
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):903-913. PubMed ID: 30667592
[TBL] [Abstract][Full Text] [Related]
3. Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects.
Osawa M; Ueno T; Shiozaki T; Li H; Garimella T
J Clin Pharmacol; 2019 Apr; 59(4):557-565. PubMed ID: 30566237
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.
Esposito I; Marciano S; Trinks J
Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):649-657. PubMed ID: 29855221
[TBL] [Abstract][Full Text] [Related]
5. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Poordad F; Sievert W; Mollison L; Bennett M; Tse E; Bräu N; Levin J; Sepe T; Lee SS; Angus P; Conway B; Pol S; Boyer N; Bronowicki JP; Jacobson I; Muir AJ; Reddy KR; Tam E; Ortiz-Lasanta G; de Lédinghen V; Sulkowski M; Boparai N; McPhee F; Hughes E; Swenson ES; Yin PD;
JAMA; 2015 May; 313(17):1728-35. PubMed ID: 25942723
[TBL] [Abstract][Full Text] [Related]
6. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD
JAMA; 2015 May; 313(17):1736-44. PubMed ID: 25942724
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Osawa M; Ueno T; Ishikawa H; Imai Y; Garimella T
J Clin Pharmacol; 2018 Nov; 58(11):1468-1478. PubMed ID: 30063254
[TBL] [Abstract][Full Text] [Related]
8. Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
Garimella T; Tao X; Sims K; Chang YT; Rana J; Myers E; Wind-Rotolo M; Bhatnagar R; Eley T; LaCreta F; AbuTarif M
Drugs R D; 2018 Mar; 18(1):55-65. PubMed ID: 29255971
[TBL] [Abstract][Full Text] [Related]
9. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Toyota J; Karino Y; Suzuki F; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; Hu W; McPhee F; Linaberry M; Yin PD; Swenson ES; Kumada H
J Gastroenterol; 2017 Mar; 52(3):385-395. PubMed ID: 27502287
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Zappulo E; Scotto R; Buonomo AR; Maraolo AE; Pinchera B; Gentile I
Expert Opin Pharmacother; 2020 Feb; 21(3):261-273. PubMed ID: 31914336
[No Abstract] [Full Text] [Related]
11. Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
Thiam A; Conway B
Drugs Today (Barc); 2018 Apr; 54(4):237-244. PubMed ID: 29869645
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.
Kao JH; Yu ML; Peng CY; Heo J; Chu CJ; Chang TT; Lee YJ; Hu TH; Yoon KT; Paik SW; Lim YS; Ahn SH; Isakov V; McPhee F; Hu W; Scott Swenson E; Yin PD; Treitel M
J Gastroenterol Hepatol; 2017 Dec; 32(12):1998-2005. PubMed ID: 28370350
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
Eley T; Sevinsky H; Huang SP; He B; Zhu K; Kandoussi H; Gardiner D; Grasela DM; Bertz R; Bifano M
Clin Drug Investig; 2014 Sep; 34(9):661-71. PubMed ID: 25117173
[TBL] [Abstract][Full Text] [Related]
14. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Akuta N; Toyota J; Karino Y; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; McPhee F; Noviello S; Kumada H
J Gastroenterol; 2018 Sep; 53(9):1089-1097. PubMed ID: 29500489
[TBL] [Abstract][Full Text] [Related]
15. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Takaguchi K; Toyoda H; Tsutsui A; Suzuki Y; Nakamuta M; Imamura M; Senoh T; Nagano T; Tada T; Tachi Y; Hiraoka A; Michitaka K; Shibata H; Joko K; Okubo H; Tsuji K; Takaki S; Watanabe T; Ogawa C; Chayama K; Kumada T; Kudo M; Kumada H
J Gastroenterol; 2019 Aug; 54(8):742-751. PubMed ID: 30848363
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
Kato K; Shimada N; Atsukawa M; Abe H; Itokawa N; Matsumoto Y; Agata R; Tsubota A
PLoS One; 2019; 14(7):e0219022. PubMed ID: 31291311
[TBL] [Abstract][Full Text] [Related]
17. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Everson GT; Sims KD; Thuluvath PJ; Lawitz E; Hassanein T; Rodriguez-Torres M; Desta T; Hawkins T; Levin JM; Hinestrosa F; Rustgi V; Schwartz H; Younossi Z; Webster L; Gitlin N; Eley T; Huang SP; McPhee F; Grasela DM; Gardiner DF
Liver Int; 2016 Feb; 36(2):189-97. PubMed ID: 26473667
[TBL] [Abstract][Full Text] [Related]
18. Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma.
Jiang H; Kandoussi H; Zeng J; Wang J; Demers R; Eley T; He B; Burrell R; Easter J; Kadiyala P; Pursley J; Cojocaru L; Baker C; Ryan J; Aubry AF; Arnold ME
J Pharm Biomed Anal; 2015 Mar; 107():409-18. PubMed ID: 25676854
[TBL] [Abstract][Full Text] [Related]
19. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
Yang SS; Kao JH
Hepatol Int; 2016 Mar; 10(2):258-66. PubMed ID: 26542068
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.
Chan P; Li H; Zhu L; Bifano M; Eley T; Osawa M; Ueno T; Hughes E; Bertz R; Garimella T; AbuTarif M
Clin Pharmacokinet; 2017 Oct; 56(10):1173-1183. PubMed ID: 28066880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
